| Similar Articles |
|---|
 |
Pharmaceutical Executive
April 1, 2011 |
Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help.   |
Pharmaceutical Executive
September 1, 2011
Don Creighton |
Bridging the Hidden Hurdle in Cancer Cures Diagnostics can boast the efficacy of drug treatments, but delivering the promise depends on a predictable pathway to reimbursement. |
Pharmaceutical Executive
March 1, 2011
Jerry Coamey |
Engage the Physician! New research shows that gauging the mind of the clinician is crucial to timely uptake of the new diagnostic tools offered by the genomic revolution |
Pharmaceutical Executive
October 1, 2008 |
Getting Personal(ized) Stop worrying about shrinking the market for your drug, and start figuring out how the "test and treat" business model works. |
Chemistry World
July 2010
Anna Lewcock |
Medicine made to measure Healthcare tailored to suit the genetic makeup of the patient is finally coming to fruition. |
Bio-IT World
March 2007
Michael A. Greeley |
Can I Get Personal? VC's are back and seem very excited about the broader disease management and personalized medicine investment opportunities. |
Pharmaceutical Executive
February 1, 2011
Jennifer Ringler |
Skipping the Needle: Pharm Exec's Brand of the Year Novartis' Gilenya is a step forward in treating Multiple Sclerosis. But generating increased compliance is another story |
Pharmaceutical Executive
September 1, 2005
Mattingly & Saxberg |
Biomarkers Come of Age In the past five years, biomarkers have become an essential part of pharmaceutical R&D. Seven industry experts explain how it happened - and what comes next. |
Pharmaceutical Executive
October 1, 2010 |
Taking a Less-Generic Route to Generics A leading pharmaceutical industry player speaks out on what is fueling success in the sector. |
The Motley Fool
October 27, 2010
Ralph Casale |
Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment. |
Pharmaceutical Executive
September 1, 2008
Jeffrey S. Aronin |
The Orphan Opportunity The Orphan Drug Act was passed 25 years ago. But the challenge of actually getting rare disease drugs and therapies to patients still remains |
Pharmaceutical Executive
June 1, 2014
O'Connor et al. |
Challenges to the Specialty Business Model New constraints require new solutions. Innovative, value-based pricing models will be critical to securing reimbursement and continued market access of high-price drugs. |
Pharmaceutical Executive
February 1, 2013
William Looney |
Pathways to Progress Cancer is increasingly understood as a collection of rare and mostly treatable conditions rather than the impregnable, monolith portrayed in popular culture. Industry experts review current and pending efforts to turn great science into good practice. |
Pharmaceutical Executive
October 1, 2010 |
When the Payer IS the Player As Medicare, Medicaid, and the nation's web of private payers gain market power, how can pharma stay ahead of the cost-containment curve? |
The Motley Fool
June 7, 2011
Brian Orelli |
Sometimes a Partnership Feels Personal Merck and Roche hook up for a diagnostic drug deal. |
Pharmaceutical Executive
February 1, 2012
Ben Comer |
Best to Market Pharm Exec's Brand of the Year: Abbott's Humira |
Pharmaceutical Executive
September 1, 2012
Ben Comer |
You Tell Me Specialized knowledge about disease and treatment is no longer the exclusive province of practicing physicians. For biopharmaceutical manufacturers, patient feedback can help to elucidate an unmet need. |
Bio-IT World
November 14, 2003
Kathy Ordonez |
Targeted Medicine via Molecular Diagnostics Using diagnostics to select and deselect target populations for drug therapy will enable life scientists to make more effective medicines. |
Chemistry World
October 8, 2010
Sarah Houlton |
U-turn on Alzheimer's drugs in the UK The UK National Institute for Health and Clinical Excellence proposes that those with mild disease will be able to receive them from early next year, on the basis of growing clinical evidence of their effectiveness. |
The Motley Fool
May 10, 2011
Brian Orelli |
Uncontrolled Crying Over AVANIR's Prescription Data? It's been a slow start, but don't write off this company's pseudobulbar drug just yet. |
Pharmaceutical Executive
June 9, 2014
Kleinrock & Noor |
Pharm Exec's Pharma 50 2014 For those companies in this year's Pharm Exec Top 50, meeting the accelerating market demand for specialty products has become an acute strategic imperative. |
Pharmaceutical Executive
March 1, 2013
Keeling & Paz |
Early Engagement with Medical Laboratories Timely engagement is the key to expanding the use of companion diagnostics. |
Pharmaceutical Executive
July 1, 2011
Dickmeyer & Rosenbeck |
From Rut to Racetrack Can the pharmaceutical industry deliver on its objective to make cancer a curable, chronic condition? |
Pharmaceutical Executive
November 1, 2012
Sue Barrowcliffe |
Real World Insights Commercial teams as well as patients can benefit from managed access programs, which are designed to provide access to medicines outside of the clinical and commercial setting, for patients who have no other available treatment options. |
Pharmaceutical Executive
June 1, 2006
Nancy Dreyer |
Personalized Medicine Meets the Real World A wave of genomic medicines is coming down the pipeline, and they're going to be expensive. Can companies prove they're worth it? Maybe: but the claims payers seek aren't coming from traditional clinical trials. |
Pharmaceutical Executive
December 1, 2011
Ben Comer |
Pharm Exec's 2012 Pipeline Report It's a neck and neck race toward safer, faster, and medically superior treatments. Which organizations have what it takes to jockey their products into the winner's circle? |
The Motley Fool
September 7, 2010
Luke Timmerman |
Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
The Next Wave: Pharm Exec's 2011 Pipeline Report 42 of the best new drugs in development or parked at the FDA |
Pharmaceutical Executive
January 1, 2013
Al Topin |
The Doctor-Patient Disconnect Doctor-patient conversations aren't always what we think; this basic interaction represents both a problem and an opportunity for today's drug marketers, says the author. |
The Motley Fool
September 14, 2011
Frank Vinluan |
Here's How New Roche Cancer Drug Zelboraf Benefits LabCorp A new Roche cancer drug expected to become a blockbuster could also end up being a boon for laboratory and diagnostics firm LabCorp. |
Pharmaceutical Executive
July 1, 2012
Jill Wechsler |
Who Will Pay for New Drugs? Comparative research documenting value and affordability is key to obtaining coverage for high-cost therapies. |
Pharmaceutical Executive
November 1, 2013 |
Roundtable on Market Access Market Access is a window on what matters in the real world of soaring patient expectations and crimped payer budgets for innovation. |
Managed Care
May 2000
Mark G. Weiner, M.D., and Eric Pifer, M.D. |
Computerized Decision Support and the Quality of Care The notion of quality of care in medicine is not new, but it is becoming increasingly important as the competitive health care market demands objective measures to compare physicians, hospitals, and managed care organizations.... |
Bio-IT World
March 2006
Michael A. Greeley |
The Theranostics Promise A huge amount of discovery and clinical development for new drugs involves clinical trials that include companion diagnostic tests. These theranostic tests are poised to become a promising market for entrepreneurs, though challenges -- such as patent issues -- remain. |
Pharmaceutical Executive
April 1, 2011 |
Winning Beyond the Molecule It can take both a clinical and non-clinical approach to win the differentiation competition. |
American Journal of Nursing
July 2011
Brodkey et al. |
Living Well with Multiple Sclerosis Improvements in magnetic resonance imaging and the advent of disease-modifying therapies in the past 15 years have changed the diagnosis and treatment of multiple sclerosis |
Pharmaceutical Executive
August 1, 2012 |
Sunny Outlook for Biopharm 2020? Albert Wertheimer looks beyond today's dark clouds with a comparatively sunny forecast for the biopharm industry in 2020. Just watch out for the harsh light of complacency. |
Chemistry World
August 27, 2015
Phillip Broadwith |
Drugs in a class of their own In the last month, three drugs in new therapeutic classes have been approved for cardiovascular diseases. |
Nursing
June 2011
Daniel A. Hussar |
New Drugs 2011: Part 2 In this article, you'll learn about seven recently approved drugs, including: fingolimod hydrochloride, an oral drug indicated to treat patients with relapsing forms of multiple sclerosis. |
Nursing
November 2008
Michael W. Day |
Fight Back Against Inflammatory Bowel Disease It takes guts to live with Crohn's disease or ulcerative colitis, both of which can take a heavy toll on their victims. Find out how to help your patient tame the attacks. |
Pharmaceutical Executive
April 1, 2006
Christensen, McLaughlin & Wunker |
The Road to Nowhere? More effective drugs? Another dead end. But patients open their wallets when a "good enough" drug gets better. |
The Motley Fool
April 25, 2011
Luke Timmerman |
Vertex, Merck Step Up to the Public Stage With Hepatitis C Drugs This Week Most analysts see Vertex's drug as best-in-class. But what does the FDA have to say about it? |
Pharmaceutical Executive
April 1, 2014
William Looney |
The Trials of Commerce Four commercial line executives serve as our jury of peers on what's in store for the future of pharma, and discuss the changing criteria for market success, from drugs to consumer products to vaccines. |
BusinessWeek
January 21, 2010
John Carey |
Making Personalized Medicine Pay Medco and other pharmacy benefit managers say future profits depend on matching drugs to patients based on their genes. |
Pharmaceutical Executive
April 1, 2012
Feam & Lagus |
Providing Access Now While regulatory frameworks and medical practices differ between countries, many patients still need early access to new drugs. Industry can help. |
Bio-IT World
February 18, 2004 |
Pathology Goes Molecular New technologies are enabling clinical diagnostic laboratories to pave the way toward more personalized cancer therapies |
Nurse Practitioner
February 2011
Jennifer M. Belavic |
Annual Drug Update: 2010 in Review In 2010, the FDA approved several new drugs and new indications for use in primary care. From new therapies for adults with rheumatoid arthritis to a combination drug for benign prostatic hyperplasia, NPs need to be aware of the latest medications now available. |
The Motley Fool
September 24, 2010
Brian Orelli |
Prepare for This $12 Billion Whoosh Pfizer's Lipitor is the top-selling cholesterol drug -- in fact, it's the top selling drug period -- but it'll start to see generic competition in a little over a year. |
Pharmaceutical Executive
October 1, 2011
Jill Wechsler |
At the Helm of Industry As the lead FDA official overseeing the testing and approval of new drugs and biotech therapies for some 20 years, Dr. Janet Woodcock has built a robust and modern drug regulatory system. |
The Motley Fool
November 9, 2010
Brian Orelli |
Forget R&D; Buy Your Way Into Diagnostics Eli Lilly is expanding its diagnostics business by picking up privately held Avid Radiopharmaceuticals. |
